Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE2 | Q9BYF1 | 3/20 | 0.50 |
| ▸ | SLC9A1 | P19634 | 2/20 | 0.48 |
| ▸ | SLC9A2 | Q9UBY0 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | CDC25B | P30305 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | TTR | P02766 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31587739 | 1.00 | ACE2 (0.50) | ACE2SLC9A1SLC9A2KMT2ASMN1; SMN2 | |
| SCHEMBL15641748 | 0.85 | ACE2 (0.51) | ACE2SLC9A1SLC9A2KMT2ASMN1; SMN2 | |
| SCHEMBL3968070 | 0.85 | SLC9A1 (0.64) | ACE2SLC9A1SLC9A2KMT2ASMN1; SMN2 | |
| SCHEMBL2421238 | 0.83 | PKM (0.58) | ACE2SLC9A1SLC9A2KMT2ASMN1; SMN2 | |
| SCHEMBL7659788 | 0.80 | ACE2 (0.47) | ACE2SLC9A1SLC9A2KMT2ASMN1; SMN2 | |
| SCHEMBL30735778 | 0.77 | SMN1; SMN2 (0.58) | KMT2ASMN1; SMN2CDC25BPKMTDP1 | |
| SCHEMBL940404 | 0.77 | SMN1; SMN2 (0.58) | KMT2ASMN1; SMN2CDC25BPKMTDP1 | |
| SCHEMBL13816269 | 0.76 | ACE2 (0.61) | ACE2KMT2ASMN1; SMN2KDM4EGRM1 | |
| SCHEMBL7598306 | 0.75 | TSHR (0.59) | ACE2KMT2ASMN1; SMN2GRM1TDP1 | |
| SCHEMBL7922220 | 0.75 | CDC25B (0.50) | KMT2ASMN1; SMN2CDC25BKDM4EPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12485169-B2 | Compounds | Grey Wolf Therapeutics Limited (GB) | 2025-12-02 | — | — | US | disclosed |
| US-20230064417-A1 | COMPOUNDS | Grey Wolf Therapeutics Limited (GB) | 2023-03-02 | — | — | US | disclosed |
| EP-3883650-A1 | COMPOUNDS | Grey Wolf Therapeutics Limited (GB) | 2021-09-29 | — | — | EP | disclosed |
| CN-113056305-A | Compound (I) | 格雷沃尔夫治疗有限公司 | 2021-06-29 | — | — | CN | disclosed |
| EP-0921117-B2 | Acylguanidines | SANOFI AVENTIS DEUTSCHLAND (DE) | 2009-01-07 | — | — | EP | disclosed |
| WO-2005079803-A1 | COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISEASES | PFIZER PRODUCTS, INC. (US) | 2005-09-01 | — | — | WO | disclosed |
| US-6841560-B2 | Substituted isoquinoline derivatives and their use as anticonvulsants | SMITHKLINE BEECHAM P.L.C. (GB) | 2005-01-11 | — | — | US | disclosed |
| US-20040209912-A1 | Substituted isoquinoline derivatives and their use as anticonvulsants | SMITHKLINE BEECHAM P.L.C. | 2004-10-21 | — | — | US | disclosed |
| US-6762192-B2 | USEFUL IN THERAPY AND PROPHYLAXIS OF EPILEPSY, MIGRAINE, AND OTHER DISORDERS | SMITHKLINE BEECHUM P.L.C. (GB) | 2004-07-13 | — | — | US | disclosed |
| US-20040044081-A1 | Diacyl-substituted guanidines, a process for their preparation, their use as medicament or diagnostic aid, and medicament containing them | HOECHST AKTIENGESELLSCHAFT | 2004-03-04 | — | — | US | disclosed |
| US-5753710-A | INHIBITORS OF THE CELLULAR SODIUM PROTON ANTIPORTER | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-05-19 | — | — | US | disclosed |
| CN-1145360-A | Substituted benzyloxy carbonyl guanidine, its prepn. method, and application of the same as medicament and medicament containing the same | HOECHST AG (DE) | 1997-03-19 | — | — | CN | disclosed |
| EP-0589336-B1 | Benzoylguanidines, process for their preparation and their use as antiarrhythmic agents | HOECHST AG (DE) | 1997-01-08 | — | — | EP | disclosed |
| US-5591754-A | Benzoylguanidines, pharmaceutical composition containing them and treatment of arrthythmias therewith | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-01-07 | — | — | US | disclosed |
| EP-0748795-A2 | Substituted benzyloxycarbonyl guanidines as Na+/H+ exchange inhibitors, process for their preparation, their use as medicinal or diagnostic agents as well as medicament containing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1996-12-18 | — | — | EP | disclosed |
| EP-0640587-A1 | Diacyl substituted guanidins, process for their preparation, their use as medicament or diagnostic reagent and medicament containing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-03-01 | — | — | EP | disclosed |
| EP-0604852-A1 | 2,4-Substituted 5-(N-substituted-sulfamoyl) benzoylguanidines, as antiarrhythmic agents, inhibitors of the proliferation of cells and inhibitors of sodium-hydrogen exchange | HOECHST AKTIENGESELLSCHAFT (DE) | 1994-07-06 | — | — | EP | disclosed |
| EP-0589336-A1 | Benzoylguanidines, process for their preparation and their use as antiarrhythmic agents | HOECHST AKTIENGESELLSCHAFT (DE) | 1994-03-30 | — | — | EP | disclosed |
| US-4125614-A | DIURETIC | HOECHST AKTIENGESELLSCHAFT (DE) | 1978-11-14 | — | — | US | disclosed |
| US-4061761-A | Thiazolidine derivatives | HOECHST AKTIENGESELLSCHAFT (DT) | 1977-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230064417-A1 | COMPOUNDS | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HRH4, CBR3 | ACE2 2521/4885SLC9A1 18/4885SLC9A2 21/4885 |
| US-20040209912-A1 | Substituted isoquinoline derivatives and their use as anticonvulsants | INA, GRIN2C, GRIN2A | ACE2 1430/4885SLC9A1 1792/4885SLC9A2 1154/4885 |
| US-20040044081-A1 | Diacyl-substituted guanidines, a process for their preparation, their use as medicament or diagnostic aid, and medicament containing them | ADRA1B, ADRA1A, HYOU1 | ACE2 2091/4885SLC9A1 37/4885SLC9A2 112/4885 |
| US-12485169-B2 | Compounds | SLC10A1, VHL, CFTR | ACE2 701/4885SLC9A1 19/4885SLC9A2 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.